Top Tech Companies (83)
Don't see your company?
Create a company profile
A chemical and biological software development company that provides solutions for the biotechnology and pharmaceutical industries; successfully used in publishing, flavors, fragrances, petroleum and fine chemicals research as well.
ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company has assembled industry-leading talent, built state-of-the-art facilities, and integrated diverse technology platforms, including gene editing, induced pluripotent stem cells (iPSCs), and protein, vector, and cellular engineering, necessary to drive innovation and commercialization of cellular and genetic medicines. In addition, ElevateBio BaseCamp is a purpose-built, technology-enabled manufacturing platform offering process innovation, process sciences, and current Good Manufacturing Practice (cGMP) manufacturing capabilities for viral vectors, RNA, and cell therapy production. Through BaseCamp, its expanding footprint, and its next-generation enabling technologies, ElevateBio is rapidly growing its collaborations with industry partners while also selectively developing its own portfolio of cellular and genetic medicines. ElevateBio's team of scientists, drug developers, and company builders are redefining what it means to be a technology company in the world of drug development, blurring the line between technology and healthcare.
Reverie Labs is a pharmaceutical company that uses its innovative computational chemistry and machine learning tools to accelerate its drug discovery programs. Reverie's primary goal is to develop kinase inhibitors that address the unmet needs of patients.
Our team develops simple, efficient procure-to-pay solutions for biotech research organizations as they develop life-saving therapies for the world's most serious health problems. Prendio is proud to play a small part in this important healing mission.
ShapeTX is pioneering the field of programmable RNA medicines to repair the genetic causes of diseases. By merging innovations in AI and RNA technology to generate and analyze hundreds of billions of therapeutic possibilities, ShapeTX is developing breakthroughs in RNA editing, next-generation AAVs, and disruptive gene therapy manufacturing. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer’s, Parkinson’s, and many more.
Founded in 2022 and headquartered near Boston, Stellaromics is revolutionizing biomedical research with its proprietary technology, unraveling complex 3D transcription and translation patterns within native biological tissue. At the forefront of their innovation is STARmap (Spatially-resolved Transcript Amplicon Readout mapping), their flagship product. STARmap empowers researchers to uncover gene expression patterns within intact tissue, facilitating the pinpointing of treatment targets and bolstering biomedical investigations.
.jpeg)
Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. We have a proven strategy of advancing clinically validated mechanisms previously held back by limitations we overcome with our proprietary Glyph technology platform. All the therapeutic candidates in our pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects. We are led by an experienced team that was involved in inventing and developing KarXT and other neuropsychiatric medicines, and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders.
Elemental Machines is helping scientists improve experimental reproducibility and accelerate scientific discovery. With a new suite of connected products that harness the power of cloud-based software, machine learning and distributed sensors, Elemental Machines is giving scientists and researchers an easy, powerful and cost-effective solution fo
Pear Therapeutics’ patented eFormulation approach combines mobile health apps with supplements, medical foods, and pharmaceuticals, to create more efficacious treatment solutions. eFormulations are simple to use. A software access code on the product packaging provides access to Pear’s health apps. The patient takes the supplement or prescribed medication and simultaneously uses Pear’s games and apps, increasing efficacy, improving side effects, and enhancing compliance. Pear’s eFormulations are the only way to target both brain chemistry and cognitive experience simultaneously, providing an entirely new way to treat brain-related diseases.
AG Mednet’s technology solves critical problems for the pharmaceutical, biotechnology and medical device markets. As the leading partner for endpoint/adverse event adjudication and imaging data collection and QC, we work with the world’s top pharmaceutical companies and CROs.
Labviva is the SaaS digital marketplace that connects suppliers, purchasers, and scientists. Our platform seamlessly integrates with your existing procurement systems, to enable purchasing departments to take control of their supply chain by gaining greater visibility of purchasing trends and third-party tail spend, while providing a comprehensive customized marketplace that streamlines the purchasing process with existing workflows. We strive to connect researchers with suppliers of reagents, chemicals, and instrumentation in an intuitive user-friendly platform that supports the priorities of scientists while staying compliant with purchasing rules. Suppliers can easily manage their content of their products. Products are mapped into scientific applications, techniques and protocols, then a relevant a citation index score is generated based on references in peer reviewed journal and related documents and assets are compiled. The results are a unique index of products linked to the relevancy of a product with each scientific use case.
Landmark Bio is a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate development and industrialization of next-generation genomic medicine. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established to remove barriers in drug development, create accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing technologies for the new generation of medicines to come. Founding partners include Harvard University, Massachusetts Institute of Technology (MIT), Cytiva, FUJIFILM Diosynth Biotechnologies (FDB), and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Mass General Brigham, and the Dana-Farber Cancer Institute. For more information please contact [email protected]
A TARGETED APPROACH TO ACTIVATE CELLULAR CLEARANCE Caraway’s therapeutic approach leverages genetic data and unique biological understanding to develop proprietary small molecules that activate cellular clearance and recycling processes – accelerating clearance of accumulated toxic materials and defective cellular components. New insights in genetics highlight the link between lysosomal function and pathologies in multiple organ systems, including the central nervous system (CNS), heart, kidney, and muscle. Caraway is a leader in targeting these mechanisms with potentially disease-modifying compounds for patients suffering the devastating effects of neurodegenerative and rare diseases including Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), and lysosomal storage diseases (LSDs).
Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations across hard-to-treat cancers. Clasp is developing T cell engagers to match both the specific characteristics of the patient’s immune system and the specific genetics of their tumor, enabling the creation of exquisitely personalized, yet off-the-shelf, therapeutics. Built upon academic research in the labs of Bert Vogelstein and Drew Pardoll at Johns Hopkins University, Clasp is backed by prominent life sciences investors including Catalio Capital Management, Third Rock Ventures and Novo Holdings. The company was launched in March 2024 and is based in Cambridge, MA and Rockville, MD.
inviCRO is an image science company that provides advanced data analysis services and software in the growing field of pre-clinical imaging research. In collaboration with partner imaging centers, inviCRO facilitates full-service contract research imaging services utilizing SPECT, PET, MR, CT and Optical imaging technologies. To this effort, inviCRO has developed a product line of dedicated analysis and software services addressing image processing and reporting required of a pre-clinical laboratory running imaging trials.
At Scipher, we are relentlessly driven to solve one of healthcare’s biggest challenges and improve patient health outcomes. Scipher’s mission is to match each autoimmune patient with their most effective therapy. Each year, hundreds of billions of dollars are wasted prescribing drugs of limited clinical benefit to patients, even though there are often effective alternative therapies available. We believe there is a better way.
At Akili, we’re creating personalized digital therapeutics engineered to directly improve cognitive impairments. Our medicines look and feel like high-end interactive action video games but, unlike typical video games, they are informed by decades of neuroscience and built with proprietary technology developed to target and treat cognitive impairments at their specific sources in the brain. Not only is our medicine designed to target the areas of your brain that need it most, it’s designed specifically for you, adapting based on your individual needs.
High Touch Group is a privately held consultancy that helps science, engineering, and technology clients market existing products and services, showcase their value, develop and launch new products, engage with investors, generate leads, and drive revenue. We keep the science and make it exciting.
Volta Labs is a collective of antidisciplinary scientists and builders working at the intersection of engineering and biology. Our mission is clear: unlock the utility of genomics for the world. To do this, we’re building a sequencing technology agnostic platform that revolutionizes the entire sample prep process — from raw biological samples to sequenceable molecules. This makes an imagined world in which a single instrument automates the majority of biological workflows done in a lab into a reality. Our platform can handle a wide range of raw biological samples and deliver sequenceable molecules - all at the push of a button. This has required reinventing the full stack of technologies – hardware, software, chemistry, and biology.
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured.
